CoChat

Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis

Open access
Cruz-Correa, Marcia, Hylind, Linda M., Marrero, Jessica Hernandez, Zahurak, Marianna L., Murray-Stewart, Tracy, Casero, Robert A., Montgomery, Elizabeth A., Iacobuzio-Donahue, Christine, Brosens, Lodewijk A., Offerhaus, G. Johan, Umar, Asad, Rodriguez, Luz M., Giardiello, Francis M. · 2018 · Gastroenterology
Cited by 123

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background & Aims Familial adenomatous polyposis is an autosomal dominant disorder characterized by development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blind, randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. Methods Our study comprised 44 patients with familial adenomatous polyposis (18 to 85 years old) who had either not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches and had 5 or more intestinal adenomatous polyps, enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100% pure curcumin (1500 mg orally, twice per day), or identical-appearing placebo capsules, for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. Results After 1 year of treatment the average rate of compliance was 83% in the curcumin group and 91% in the placebo group. After 12 weeks, there was no significant difference between the mean number of polyps in the placebo group (18.6; 95% CI, 9.3–27.8) vs the curcumin group (22.6; 95% CI, 12.1–33.1) (P=.58). We found no significant difference between mean polyp size in the curcumin group (2.3 mm; 95% CI, 1.8–2.8) vs the placebo group (2.1 mm; 95% CI, 1.5–2.7) (P=.76). Adverse events were few with no significant differences between the groups. Conclusions In a double-blind, randomized trial of patients with familial adenomatous polyposis, we found no difference in mean number or size of lower intestinal tract adenomas between groups of patients given 3000 mg/day curcumin vs placebo for 12 weeks. Clinicaltrials.gov no: NCT00641147

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2018.05.031

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 123

Metadata

Authors
Cruz-Correa, M., Hylind, L. M., Marrero, J. H., Zahurak, M. L., Murray-Stewart, T., Casero, R. A., Montgomery, E. A., Iacobuzio-Donahue, C., Brosens, L. A., Offerhaus, G. J., Umar, A., Rodriguez, L. M., & Giardiello, F. M.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2018-09
Volume
155
Issue
3
Pages
668-673
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2804968745
Cited by
123
References
2
FWCI
3.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. https://app.cochat.ai/papers/10.1053/j.gastro.2018.05.031
The paper
Cruz-Correa, M., Hylind, L. M., Marrero, J. H., Zahurak, M. L., Murray-Stewart, T., Casero, R. A., Montgomery, E. A., Iacobuzio-Donahue, C., Brosens, L. A., Offerhaus, G. J., Umar, A., Rodriguez, L. M., & Giardiello, F. M. (2018). Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. Gastroenterology. https://doi.org/10.1053/j.gastro.2018.05.031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.